公开(公告)号：WO2012138043A3

公开(公告)日：2012-10-11

申请号：PCT/KR2011/010320

申请日：2011-12-29

Applicant: SEOUL NATIONAL UNIVERSITY HOSPITAL ,  LEE, Eun Ju ,  KIM, Hyo Soo

Inventor： LEE, Eun Ju ,  KIM, Hyo Soo

IPC: A61K31/19 ,  A61P9/10 ,  A61P9/00

Abstract: The present invention relates to a composition for preventing or treating ischemic disease comprising endothelin or a nucleotide sequence encoding endothelin as an active ingredient, and more particularly to a composition for preventing or treating ischemic heart disease, myocardial infarction, angina pectoris, lower limb artery ischemia, distal limb ischemia and ischemic cerebrovascular disease, wherein the composition is administered by intramuscular injection. According to the present invention, administering endothelin-1 by intramuscular injection may efficiently inhibit the progress of ischemia, fibrosis and tissue necrosis, and induce angiogenesis, such that it is promising for preventing or treating the ischemic disease.

公开(公告)号：WO2012096461A3

公开(公告)日：2012-09-07

申请号：PCT/KR2011010159

申请日：2011-12-27

Applicant: SEOUL NAT UNIV HOSPITAL ,  LEE EUN JU ,  KIM HYO SOO

Inventor： LEE EUN JU ,  KIM HYO SOO

IPC: C12N5/0775 ,  C07D213/72 ,  C12N5/02

CPC classification number: C12N5/0018 ,  A61K31/4409 ,  C12N5/0663 ,  C12N2501/727

Abstract: The present invention relates to a composition for suppressing cell death of stem cells during suspension culturing, a composition for mass culturing of stem cells, and a method for suppressing cell death of stem cells during suspension culturing. The composition of the present invention can be usefully used for effective single suspension culturing of stem cells, particularly, mesenchymal stem cells, or used for mass suspension culturing under the circumstances in which cell aggregation does not occur.

Abstract translation: 本发明涉及一种用于抑制悬浮培养期间干细胞的细胞死亡的组合物，用于干细胞的大规模培养的组合物，以及用于在悬浮培养期间抑制干细胞的细胞死亡的方法。 本发明的组合物可有效地用于干细胞，特别是间充质干细胞的有效单悬液培养，或者在不发生细胞聚集的情况下用于大量悬浮培养。

公开(公告)号：WO2011129607A3

公开(公告)日：2012-03-08

申请号：PCT/KR2011002622

申请日：2011-04-13

Applicant: SEOUL NAT UNIV HOSPITAL ,  KIM HYO-SOO ,  LEE EUN-JU ,  KANG HYUN-JAE

Inventor： KIM HYO-SOO ,  LEE EUN-JU ,  KANG HYUN-JAE

IPC: C12N5/0775 ,  A63C17/02 ,  A63C17/22

CPC classification number: C12N5/0665 ,  A61K35/28 ,  C12N2501/365

Abstract: Disclosed is a method for increasing the activity of human stem cells. The method is characterized by treating a culture medium with endothelin-1. Also, the highly active human stem cells prepared by the method and cell therapeutics comprising the highly active human stem cells are provided. Human mesenchymal stem cells of various origins can be activated by the method, and thus resulting highly active human mesenchymal stem cells can be developed as effective cell therapeutics.

Abstract translation: 公开了增加人类干细胞活性的方法。 该方法的特征在于用内皮素-1处理培养基。 此外，提供了通过包含高活性人干细胞的方法和细胞治疗剂制备的高活性人干细胞。 可以通过该方法活化各种来源的人间充质干细胞，因此可以开发出高活性的人类间充质干细胞作为有效的细胞治疗剂。

公开(公告)号：WO2006019203A1

公开(公告)日：2006-02-23

申请号：PCT/KR2004/002320

申请日：2004-09-14

Applicant: SEOUL NATIONAL UNIVERSITY INDUSTRY FOUNDATION ,  STENTECH. INC. ,  KIM, Hyo-Soo ,  KOO, Bon-Kwon ,  KANG, Hyun-Jae ,  YANG, Han-Mo ,  KWON, Byung-Doo

Inventor： KIM, Hyo-Soo ,  KOO, Bon-Kwon ,  KANG, Hyun-Jae ,  YANG, Han-Mo ,  KWON, Byung-Doo

IPC: A61K31/415

CPC classification number: A61K31/415

Abstract: This invention is directed to the use of certain pharmaceutical compositions containing celecoxib for preventing and treating vascular restenosis. The pharmaceutical compounds including celecoxib of the present invention can significantly reduce neointimal hyperplasia through an inhibition of VSMC (vascular smooth muscle cell) proliferation and an increase in VSMC apoptosis. From these results, celecoxib can be used for preventing and treating artery restenosis.

Abstract translation: 本发明涉及含塞来昔布的某些药物组合物用于预防和治疗血管再狭窄的用途。 包括本发明的塞来昔布的药物化合物可通过抑制VSMC（血管平滑肌细胞）增殖和VSMC凋亡的增加而显着减少新生内膜增生。 从这些结果可以看出，塞来昔布可用于预防和治疗动脉再狭窄。

公开(公告)号：WO2013032158A3

公开(公告)日：2013-04-25

申请号：PCT/KR2012006572

申请日：2012-08-17

Applicant: SNU R&DB FOUNDATION ,  KIM HYO-SOO ,  LEE SAE-WON ,  YOUN SEOCK-WON

Inventor： KIM HYO-SOO ,  LEE SAE-WON ,  YOUN SEOCK-WON

IPC: C12N5/0775 ,  A61K31/7088 ,  C12N1/38

CPC classification number: C12N5/0658 ,  C12N2501/17

Abstract: The present invention relates to a method which makes use of either Ang1 (angiopoietin 1) or COMP-Ang1 (cartilage oligomeric matrix protein-angiopoietin 1), which regulate the differentiation mechanism of stem cells, so as to induce specific differentiation into muscle cells. Provided are a composition which is highly efficient in inducing differentiation from stem cells into muscle cells, and a therapeutic composition for diseases involving muscle damage using the differentiation-inducing ability. Consequently, the outstanding activity of the composition of the present invention can be used to advantage in the alleviation or treatment of diseases involving muscle damage such as muscular dystrophy, muscle inflammation and fibrosis.

Abstract translation: 本发明涉及利用调节干细胞分化机制的Ang1（血管生成素1）或COMP-Ang1（软骨寡聚基质蛋白 - 血管生成素1）以诱导特异性分化为肌细胞的方法。 本发明提供一种诱导干细胞向肌细胞的分化高度有效的组合物以及使用该分化诱导能力的肌肉损伤相关疾病的治疗组合物。 因此，本发明组合物的突出活性可用于减轻或治疗涉及肌肉损伤的疾病，例如肌营养不良，肌肉炎症和纤维化。

公开(公告)号：WO2013022262A2

公开(公告)日：2013-02-14

申请号：PCT/KR2012006269

申请日：2012-08-07

Applicant: SEOUL NAT UNIV HOSPITAL ,  PARK YOUNG BAE ,  KIM HYO SOO ,  KWON YOO WOOK ,  LEE SAH MIN ,  LEE HYUN CHAE ,  CHO YOUNG JIN ,  LEE SANG EUN ,  CHUNG JUN HO

Inventor： PARK YOUNG BAE ,  KIM HYO SOO ,  KWON YOO WOOK ,  LEE SAH MIN ,  LEE HYUN CHAE ,  CHO YOUNG JIN ,  LEE SANG EUN ,  CHUNG JUN HO

IPC: G01N33/68 ,  A61K38/00 ,  C12N15/62 ,  C12N15/85

CPC classification number: C07K14/5759 ,  C07K2319/30

Abstract: The present invention relates to a human resistin receptor. More specifically, provided are a method for searching for a receptor for a human resistin protein, a method for preventing or treating inflammatory diseases and atherosclerosis using a regulator which regulates the expression or activity of a human resistin receptor, and a pharmaceutical composition containing a regulator which regulates the expression or activity of a human resistin receptor. It is possible to separate a receptor which directly binds to resistin from human monocytes using the method for searching for a receptor for a human resistin protein of the present invention, and the discovery of the signal delivery system of a resistin receptor is expected to contribute to the regulation of inflammatory effects of a monocyte, the diagnosis of the molecular cause of blood vessel inflammation and atherosclerosis, and the development of an agent for preventing and treating inflammatory diseases and atherosclerosis.

Abstract translation: 本发明涉及人抵抗素受体。 更具体而言，提供了用于检索人抵抗素蛋白的受体的方法，使用调节人抵抗素受体的表达或活性的调节剂来预防或治疗炎性疾病和动脉粥样硬化的方法，以及含有调节剂的药物组合物 其调节人抵抗素受体的表达或活性。 使用本发明的人抵抗素蛋白质受体的检索方法，可以将与人抵抗素直接结合的受体从人单核细胞中分离出来，发现抵抗素受体的信号传递系统有助于 单核细胞炎症作用的调节，血管炎症和动脉粥样硬化的分子病因的诊断，以及炎症性疾病和动脉粥样硬化的预防和治疗剂的开发。

公开(公告)号：WO2012026687A3

公开(公告)日：2012-04-19

申请号：PCT/KR2011005762

申请日：2011-08-08

Applicant: UNIV SEOUL NAT R & DB FOUND ,  PARK YOUNG-BAE ,  KIM HYO-SOO ,  KANG HYUN-JAE ,  CHO HYUN-JAI ,  HUR JIN ,  PARK JONG-HAN ,  JANG JAE-HEE

Inventor： PARK YOUNG-BAE ,  KIM HYO-SOO ,  KANG HYUN-JAE ,  CHO HYUN-JAI ,  HUR JIN ,  PARK JONG-HAN ,  JANG JAE-HEE

IPC: C12N5/0789 ,  C12N5/02 ,  C12N5/0786

CPC classification number: C12N5/0647 ,  C12N5/0634 ,  C12N2502/1157 ,  C12N2513/00

Abstract: The present invention relates to a technique of using monocytic blood cells to effectively culture and proliferate blood adult stem cells and progenitor cells that only exist in small quantities to effectively obtain large quantities of stem cells. According to the present invention, the limitation of being able to derive only small quantities of stem cells from blood can be overcome, and the pluripotency of stem cells can easily be obtained.

Abstract translation: 本发明涉及使用单核细胞血细胞有效地培养和增殖仅存在少量的血液成体干细胞和祖细胞以有效获得大量干细胞的技术。 根据本发明，可以克服仅能够从血液中得到少量干细胞的限制，并且可以容易地获得干细胞的多能性。

公开(公告)号：WO2011052950A2

公开(公告)日：2011-05-05

申请号：PCT/KR2010/007344

申请日：2010-10-25

Applicant: LG LIFE SCIENCES LTD. ,  KIM, Soon Ha ,  KIM, Hyoung Jin ,  PARK, Heui Sul ,  GU, Seon Yeong ,  KWAK, Hyo Shin ,  PARK, Du Hee ,  KIM, Hyo Soo ,  CHO, Hyun Jai ,  KIM, Ji Hyun ,  KIM, Ju Young ,  PARK, Kwang Min

Inventor： KIM, Soon Ha ,  KIM, Hyoung Jin ,  PARK, Heui Sul ,  GU, Seon Yeong ,  KWAK, Hyo Shin ,  PARK, Du Hee ,  KIM, Hyo Soo ,  CHO, Hyun Jai ,  KIM, Ji Hyun ,  KIM, Ju Young ,  PARK, Kwang Min

IPC: A61K31/404 ,  A61P29/00 ,  A61P19/02 ,  A61P7/08 ,  A61P19/10

CPC classification number: A61K31/541 ,  A61K8/492 ,  A61K31/404 ,  A61K31/4184 ,  A61K31/427 ,  A61K31/496 ,  A61K31/497 ,  A61K2800/522 ,  A61Q19/00 ,  C07D413/04 ,  C07D417/04 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04

Abstract: The present invention relates to a pharmaceutical composition comprising a compound of formula (1), (2) or (3) as defined in the specification for the prevention or treatment of diseases associated with oxidative stress, mitochondria dysfunction, hypoxic injury, necrosis and/or ischemic reperfusion injury, and a cosmetic composition comprising an indole compound having an antioxidant effect.

Abstract translation: 本发明涉及药物组合物，其包含如说明书中定义的式（1），（2）或（3）化合物，其用于预防或治疗与氧化应激，线粒体功能障碍，缺氧损伤，坏死和/ 或缺血再灌注损伤，以及包含具有抗氧化作用的吲哚化合物的化妆品组合物。

公开(公告)号：WO2012138043A2

公开(公告)日：2012-10-11

申请号：PCT/KR2011010320

申请日：2011-12-29

Applicant: SEOUL NAT UNIV HOSPITAL ,  LEE EUN JU ,  KIM HYO SOO

Inventor： LEE EUN JU ,  KIM HYO SOO

IPC: A61K31/19 ,  A61P9/00 ,  A61P9/10

CPC classification number: A61K38/2278

Abstract: The present invention relates to a composition for preventing or treating ischemic disease comprising endothelin or a nucleotide sequence encoding endothelin as an active ingredient, and more particularly to a composition for preventing or treating ischemic heart disease, myocardial infarction, angina pectoris, lower limb artery ischemia, distal limb ischemia and ischemic cerebrovascular disease, wherein the composition is administered by intramuscular injection. According to the present invention, administering endothelin-1 by intramuscular injection may efficiently inhibit the progress of ischemia, fibrosis and tissue necrosis, and induce angiogenesis, such that it is promising for preventing or treating the ischemic disease.

Abstract translation: 本发明涉及用于预防或治疗缺血性疾病的组合物，其包含内皮素或编码内皮素作为活性成分的核苷酸序列，更具体地涉及用于预防或治疗缺血性心脏病，心肌梗死，心绞痛，下肢动脉缺血的组合物 ，远端肢体缺血和缺血性脑血管疾病，其中所述组合物通过肌内注射施用。 根据本发明，通过肌内注射给予内皮素-1可有效抑制缺血，纤维化和组织坏死的进展，并诱导血管发生，从而有希望预防或治疗缺血性疾病。

公开(公告)号：WO2010013906A2

公开(公告)日：2010-02-04

申请号：PCT/KR2009003954

申请日：2009-07-17

Applicant: SEOUL NAT UNIV HOSPITAL ,  KIM HYO SOO ,  LEE EUN JU ,  KANG HYUN JAE ,  LEE HA NEUL ,  KIM KEUM HYUN

Inventor： KIM HYO SOO ,  LEE EUN JU ,  KANG HYUN JAE ,  LEE HA NEUL ,  KIM KEUM HYUN

IPC: C12N5/0775

CPC classification number: C12N5/0665 ,  C12N5/0662 ,  C12N2500/90

Abstract: The present invention relates to a method for separating highly active stem cells from human stem cells, the highly active stem cells separated by the method, a cell therapeutic agent containing the stem cells, and a medium for separating the highly active stem cells from stem cells containing a specific cytokine. According to the present invention, the method is useful for separating the highly efficient stem cells from mesenchymal stem cells of various origins. Further, the method is very useful in developing a cell therapeutic agent of high efficiency because the method can be applicable to stem cells of various origins which are cultured under different conditions. Senescent stem cells increased by several passage times in vitro can be effectively sorted out, so the method can be used for reactivating the stem cells.

Abstract translation: 本发明涉及从人干细胞分离高活性干细胞的方法，通过该方法分离的高活性干细胞，含有该干细胞的细胞治疗剂和用于将高活性干细胞与干细胞分离的介质 含有特定的细胞因子。 根据本发明，该方法可用于从各种来源的间充质干细胞中分离高效干细胞。 此外，该方法在开发高效率的细胞治疗剂方面非常有用，因为该方法可适用于在不同条件下培养的各种来源的干细胞。 衰老干细胞体外传代几次后能够被有效分离出来，因此该方法可用于再生干细胞。